Conjugates for the prevention and treatment of sepsis
Patent 5545721 Issued on August 13, 1996. Estimated Expiration Date: December 17, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
530/391.7, Conjugated to a cytotoxic agent, drug, or other biologically-active substance530/300, PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES530/317, Cyclic peptides530/319, Polymyxin; related peptides530/322, Peptides containing saccharide radicals, e.g., bleomycins, etc.530/345, Chemical aftertreatment, e.g., acylation, methylation, etc.530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/391.1, Monoclonal or polyclonal antibody or immunoglobulin or fragment thereof that is conjugated or adsorbed (e.g., adsorbed to a solid support, etc.)530/391.5, Conjugated via a specifically-identified linking group, chelating group, coordination complex, coupling agent, or conjugation agent530/391.9, Conjugated via a specifically-identified linking group, coupling agent, or conjugation agent530/402Chemical modification or the reaction product thereof, e.g., covalent attachment or coupling, etc.
Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided. Conjugates and methods of making conjugates for the prevention and treatment of sepsis are described.
Other References
G. W. Machiedo et al., "Patterns of Mortality in a Surgical Intensive Care Unit," Surg. Gyn. & Ob., 152:757-759 (1981)
D. D. Morris et al., "Endotoxemia in Neonatal Calves Given Antiserum to a Mutant Escherichia coli(J-5)," Am. J. Vet. Res., 47:2554-2565 (1986)
A. M. Hoffman et al., "Prognostic Variables for Survival of Neonatal Foals Under Intensive Care," J. Vet. Int. Med., 6:89-95 (1992)
S. M. Wolff, "Monoclonal Antibodies and the Treatment of Gram-Negative Bacteremia and Shock," New Eng. J. Med., 324:486-488 (1991)
D. C. Morrison, "Bacterial Endotoxins and Pathogenesis," Rev. Infect. Dis., 5(Supp 4):S733-S747 (1983)
R. C. Bone, "The Pathogenesis of Sepsis," Ann. Intern. Med., 115:457-469 (1991)
K. J. Tracey et al., "Shock and Tissue Injury Induced by Recombinant Human Cachectin," Science 234:470-474 (1986)
A. Tewari et al., "Preliminary Report: Effects of Interleukin-1 on Platelet Counts," Lancet 336:712-714 (1990)
J. B erdy, "Recent Developments of Antibiotic Research and Classification of Antibiotics According to Chemical Structure," in Advances in Applied Microbiology, (D. Perlman, ed.), Academic Press, New York, 18:309-406 (1974)
D. G. Maki, "Nosocomial Bacteremia: An Epidemiologic Overview," Am. J. Med., 70:719-732 (1981)
J. L. Shenep and K. A. Morgan, "Kinetics of Endotoxin Release During Antibiotic Therapy for Experimental Gram-Negative Bacterial Sepsis, " J. Inf. Dis., 150:380-388 (1984)
D. C. Morrison and D. M. Jacobs, "Binding of Polymyxin B to the Lipid A Portion of Bacterial Lipopolysaccharides," Immunochem., 13:813-818 (1976)
D. Rifkind and J. D. Palmer, "Neutralization of Endotoxin Toxicity in Chick Embryos by Antibiotics," J. Bact., 92:815-819 (1966)
D. C. Morrison and D. M. Jacobs, "Inhibition of Lipopolysaccharide-Initiated Activation of Serum Complement by Polmyxin B," Infect. Immun., 13:298-301 (1976)
M. S. Cooperstock, "Inactivation of Endotoxin B," Antimicrob. Agents Chemother., 6:422-425 (1974)
Physicians' Desk Reference, 47th Ed., pp. 818-819 (1993)
P. E. Hallaway et al., "Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers," Proc. Natl. Acad. Sci. USA 86:10108-10112 (1989)
M. J. Poznansky and L. G. Cleland, "Biological Macromolecules as Carriers of Drugs and Enzymes," in Drug Delivery Systems: Characteristics and Biomedical Applications, (R. L. Juliano ed.), Oxford University Press, New York, pp. 253-315 (1980)
L. Molteni, "Dextrans as Drug Carriers," in Drug Carriers in Biology and Medicine, (G. Gregoriadis, ed.) Academic Press, New York, pp. 107-125 (1979)
C. Larsen, "Dextran Prodrugs-Structure and Stability in Relation to Therapeutic Activity," Adv. Drug Delivery Rev., 3:103-154 (1989)
A. D. Virnik et al., "Dextran and Its Derivatives," Russian Chem. Rev., 44:588-602 (1975)
G. Brownlee et al., "The Chemotherapy and Pharmacology of The Polymyxins," Brit. J. Pharmacol., 7:170-188 (1952)
Reynolds et al., in Martindale--The Extra Pharmacopoeia, 30th Ed., The Pharmaceutical Press, London, pp. 650-652 (1993)
W. A. Gibby et al., "Biodistribution and Magnetic Resonance Imaging of Cross-Linked DTPA Polysaccharides," Invest. Radio., 25:164-172 (1990)
J. J. Corrigan, Jr. and B. M. Bell, "Endotoxin-Induced Intravascular Coagulation: Prevention with Polymyxin B Sulfate," J. Lab. Clin. Med., 77:802-810 (1971)
B. Hughes et al., "Polymyxin B Sulphate Protects Cats Against the Haemodynamic and Metabolic Effects of E. coli Endotoxin," Br. J. Pharmac., 74:701-707 (1981)
J. J. Corrigan, Jr. and J. F. Kiernat, "Effect of Polymyxin B Sulfate on Endotoxin Activity in a Gram-Negative Septicemia Model," Pediat. Res., 13:48-51 (1979)
G. Ziv and W. D. Schultze, "Influence of Intrammary Infusion of Polymyxin B on the Clinicopathologic Course of Endotoxin-Induced Mastitis," Am. J. Vet. Res., 44:1446-1450 (1982)
G. Baldwin et al. "Effect of Polymyxin B on Experimental Shock from Meningococcal and Escherichia coli Endotoxins," J. Infect. Dis., 164:542-549 (1991)
A. H. L. From et al., "Polymyxin B Sulfate Modification of Bacterial Endotoxin: Effects on the Development of Endotoxin Shock in Dogs,"Infect. Immun., 23:660-664 (1979)
C. J. Ingoldby et al., "Endotoxemia in Human Obstructive Jaundice: Effect of Polymyxin B," Am. J. Surgery 147:766-771 (1984)
C. J. H. Ingoldby, "The Value of Polymixin B in Endotoxaemia Due to Experimental Obstructive Jaundice and Mesenteric Ischaemia," Br. J. Surg., 67:565-567 (1980)
J. W. Walterspiel et al., "Protective Effect of Subinhibitory Polymyxin B Alone and in Combination with Ampicillin for Overwhelming Haemophilus influenzae Type B Infection in the Infant Rat: Evidence for in Vivo and in Vitro Release of Free Endotoxin after Ampicillin Treatment," Pediat. Res., 20:237-241 (1986)
A. M. Munster et al., "Control of Endotoxemia in Burn Patients by Use of Polymyxin B," J. Burn Care Rehab., 10:327-330 (1989)
J. D. Baumgartner and M. P. Glauser, "Controversies in the Use of Passive Immunotherapy for Bacterial Infections in the Critically Ill Patient," Rev. Infect. Dis., 9:194-205 (1987)
E. J. Ziegler, "Protective Antibody to Endotoxin Core: The Emperor's New Clothes?," J. Infect. Dis., 158:286-290 (1988)
W. R. McCabe et al., "Type-Specific and Cross-Reactive Antibodies in Gram-Negative Bacteremia," New Eng. J. Med., 287:261-267 (1972)
A. I. Braude et al., "Antibody to Cell Wall Glycolipid of Gram-Negative Bacteria: Induction of Immunity of Bacteremia and Endotoxemia,"J. Infect. Dis., 136(Supp):S167-S173 (1977)
J. E. Pennington and E. Menkes, "Type-Specific vs. Cross-Protective Vaccination for Gram-Negative Bacterial Pneumonia," J. Infect. Dis., 144:599-603 (1981)
E. J. Ziegler et al., "Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia coli," New. Eng. J. Med., 307:1225-1230 (1982)
W. R. McCabe et al., "Immunization with Rough Mutants of Salmonella minnesota: Protective Activity of IgM and IgG Antibody to the R595 (Re Chemotype) Mutant," J. Infect. Dis., 158:291-300 (1988)
D. L. Dunn et al., "Anticore Endotoxin F(ab')2 Equine Immunoglobulin Fragments Protect Against Lethal Effects of Gram-Negative Bacterial Sepsis," Surgery 96:440-446 (1984)
S. J. Spier et al., "Protection Against Clinical Endotoxemia in Horses by Using Plasma Containing Antibody to an Rc Mutant E. coli (J5)," Circulatory Shock 28:235-248 (1989)
N. N. H. Teng et al., "Protection Against Gram-Negative Bacteremia and Endotoxemia with Human Monoclonal IgM Antibodies," Proc. Natl. Acad. Sci. USA 82:1790-1794 (1985)
E. J. Ziegler et al., "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody Against Endotoxin,"New. Eng. J. Med., 324:429-436 (1991)
R. L. Greenman et al., "A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis," JAMA 266:1097-1102 (1991)
K. A. Schulman et al., "Cost-Effectiveness of HA-1A Monoclonal Antibody for Gram-Negative Sepsis: Economic Assessment of a New Therapeutic Agent," JAMA 266:3466-3471 (1991)
K. Ohlsson et al., "Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock," Nature 348:550-552 (1990)
S. M. Opal et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with Pseudomonas Aeruginosa," J. Infect. Dis., 161:1148-1152 (1990)
J.-D. Baumgartner et al., "Prevention of Gram-Negative Shock and Death in Surgical Patients by Antibody to Endotoxin Core Glycolipid,"Lancet 2:59-63 (1985)
T. Calandra et al., "Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial," J. Infect. Dis., 158:312-319 (1988)
S. Harkonen et al., "Phase I Study of a Murine Monoclonal Anti-Lipid A Antibody in Bacteremic and Nonbacteremic Patients," Antimicrob. Agents Chemother., 32:710-716 (1988)
C. J. Fisher et al., "Initial Evaluation of Human Monoclonal Anti-Lipid A Antibody (HA-1A) in Patients with Sepsis Syndrome," Clin. Care Med., 18:1311-1315 (1990)
C. H. J. Ford et al., "Antibody Mediated Targeting of Radioisotopes, Drugs and Toxins in Diagnosis and Treatment," Indian J. Pediatr., 57:29-46 (1990)
H. F. Deutsch, "Preparation of Immunoglobulin Concentrates," in Methods in Immunology and Immunochemistry, (C. A. Williams and M. W. Chase, eds.), Academic Press, New York, pp. 315-321 (1967)
E. J. Cohn et al., "Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids," J. Am. Chem. Soc., 68:459-475 (1946)
G. L. Mandell and M. A. Sande, "Antimicrobial Agents: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics," in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., (Gilman, Rall, Nies, and Taylor, eds.), Pergamon Press, New York, 46:1065-1097 (1990)
M. A. Sande and G. L. Mandell, "Antimicrobial Agents: Tetracyclines, Chloramphenicol, Erythromycin, and Miscellaneous Antibacterial Agents," in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., (Gilman, Rall, Nies, and Taylor, eds.), Pergamon Press, New York, 48:1117-1145 (1990)
A. Fiechter, "Biosurfactants: Moving Towards Industrial Application," Trends in Biotech., 10:208-217 (1992)
G. L. Mandell and M. A. Sande, "Antimicrobial Agents: Drugs Used in the Chemotherapy of Tuberculosis and Leprosy," in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., (Gilman, Rall, Nies, and Taylor, eds.), Pergamon Press, New York, 49:1146-1164 (1990)
R. G. Douglas, "Antimicrobial Agents: Antiviral Agents," in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., (Gilman, Rall, Nies, and Taylor, eds.), Pergamon Press, New York, 51:1182-1201 (1990)
J. E. Bennett, "Antimicrobial Agents: Antifungal Agents," in Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 8th Ed., (Gilman, Rall, Nies, and Taylor, eds.), Pergamon Press, New York, 50:1165-1181 (1990)
T. Nakamura et al., "Tachyplesin, a Class of Antimicrobial Peptide from the Hemocytes of the Horseshoe Crab (Tachypleus tridentatus): Isolation and Chemical Structure," J. Biol. Chem., 263:16709-16713 (1988)
G. Alpert et al, "Limulus Antilipopolysaccharide Factor Protects Rabbits from Meningococcal Endotoxin Shock," Journal of Infectious Diseases 165:494-500 (1992)
R. R. Schumann et al., "Structure and Function of Lipopolysaccharide Binding Protein," Science 249:1429-1431 (1990)
M. N. Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin," J. Immunol., 148:532-537 (1992)
Pierce Chemical Co., (Rockford, IL), General Catalog, pp. E-10-E-39 (1992)
R. Berkow and A. J. Fletcher (eds), The Merck Manual, 16th ed., p. 46, (1992)
G. F. Brooks et al., Jawetz, Melnick & Adelberg's Medical Microbiology, 19th ed., pp. 172-173, (1991)
I. S. Snyder and R. G. Finch, "Basic Concepts of Chemotherapy,"in Modern Pharmacology, 2d Ed., (C. R. Craig and R. E. Stitzel, eds.), Little, Brown and Company, Boston, 45:631-640 (1986)
J. E. Conte, Jr. and S. L. Barriere, "Antibiotic Susceptibilities,"Manual of Antibiotics and Infectious Diseases, 6th Ed., Lea and Febiger, Philadelphia, Sec. IV, pp. 135-152 (1988)
L. E. Hood et al., Immunology, 2d Ed., The Benjamin/Cummings Publishing Company, Inc., Menlo Park, pp. 339-340 (1984)
M. Pollack et al., "Enhanced Survival in Pseudomonas aeruginosa Septicemia Associated with High Levels of Circulating Antibody to Escherichia coli Endotoxin Core," J. Clin. Invest., 72:1874-1881 (1983)
S. H. Zinner and W. R. McCabe, "Effects of IgM and IgG Antibody in Patients with Bacteremia Due to Gram-negative Bacilli," J. Infect. Dis., 133:37-45 (1976)
B. J. Stoll et al., "Antibodies to Endotoxin Core Determinants in Normal Subjects and in Immune Globulins for Intravenous Use,"Serodiagnosis and Immunotherapy 1:21-31 (1987)
W. Marget et al., "Lipid A Antibody Determinations Using ELISA on Patients at a Children's Hospital: A Preliminary Report," Infection 11:84-86 (1983)
C. Stoll et al., "Serum Antibodies Against Common Antigens of Bacterial Lipopoly-saccharides in Healthy Adults and in Patients with Multiple Myeloma," Infection 13:115-119 (1985)
M. Sela, "Immunological Studies with Synthetic Polypeptides," in Advances in Immunology, vol. 5, (F. Dixon and J. Humphrey, eds.), pp. 29-129 (1966)
E. S. Caplan and N. Hoyt, "Infection Surveillance and Control in the Severely Traumatized Patient," Am. J. Med., 70:638-640 (1981)
M. Meek et al., "The Baltimore Sepsis Scale: Measurement of Sepsis in Patients with Burns Using a New Scoring System," J. Burn Care Rehab., 12:564-568 (1991)
T. J. Zuerlein et al., "Superficial Cultures in Neonatal Sepsis Evaluations: Impact on Antibiotic Decision Making," Clin. Ped., 29:445-447 (1990)
R. L. Nichols, "Classification of Surgical Wounds and Nonoperative Factors Influencing Surgical Wound Infection," Decision Making in Surgical Sepsis, B. C. Decker, Inc., Philadelphia, pp. 20-21 (1991)
M. A. Awad et al., "Plasma Endotoxin and Glycolipid Antibodies in Children with Meningitis," Acta Paediatr., 81:560-561 (1992)
W. K. Joklik et al. (eds), Zinsser Microbiology, 18th ed., Appleton-Century-Crofts, Norwalk, CT (1984)
J. M. Slack and I. S. Snyder, Bacteria and Human Disease, pp. 128-133, Yearbook Medical Publishers (1978)
P. Y. Paterson, "Central Nervous System Infection: General Considerations," Biologic and Clinical Basis of Infectious Diseases, 3d ed., (G. P. Youmans et al., eds.), W. B. Saunders Co. pp. 553-568, (1985)
K. Hanasawa et al., "New Approach to Endotoxic and Septic Shock by Means of Polymyxin B Immobilized Fiber," Surg. Gyn. & Ob., 168:323-331 (1989)
K. W. Talmadge and C. J. Siebert, "Efficient Endotoxin Removal with a New Sanitizable Affinity Column: Affi-Prep Polymyxin," J. Chrom., 476:175-185 (1989)
T. Kitagawa et al., "Sensitive Enzyme Immunoassay of Colistin and Its Application to Detect Residual Colistin in Rainbow Trout Tissue," J. Assoc. Anal. Chem., (1985)
J. F. Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, New York, p. 84 (1986)
S. Barandun et al., "Intravenous Administration of Human γ-Globulin," Vox Sang., 7:157-174 (1962)
A. Chonn et al., "The Role of Surface Charge in The Activation of The Classical and Alternative Pathways of Complement by Liposomes," J. Immunol., 146:4234-4241 (1991)
C. Galanos et al., "Galactosamine-Induced Sensitization to the Lethal Effects of Endotoxin," Proc. Natl. Acad. Sci. USA 76:5939-5943 (1979)
D. J. Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy,"Nature 337:525-531 (1989)
A. Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-Immunoglobulin Molecules," Nature 339:68-70 (1989)
V. Lehmann et al., "Lethal Toxicity of Lipopolysaccharide and Tumor Necrosis Factor in Normal and D-Galactosamine-Treated Mice,"J. Exp. Med., 165:657-663 (1987)
M. A. Freudenberg and C. Galanos, "Induction of Tolerance to Lipopolysaccharide (LPS)-D-Galactosamine Lethality by Pretreatment with LPS is Mediated by Macrophages," Infect. Immun., 56:1352-1357 (1988)
F. Mosteller et al., in Probability with Statistical Applications, Addison Wesley, Reading, MA (1970)
J. F. Zilva and P. R. Pannall, Clinical Chemistry in Diagnosis and Treatment, Yearbook Medical Publishers, Chicago, IL (1984)
Raff et al., "Comparison of Functional Activities Between IgG1 and IgM Class-Switched Human Monoclonal Antibodies Reactive with Group B Streptococci or Escherichia coli K1," J. Infect. Dis., 163:346-354 (1991)
Rozenberg-Arska et al., "Bactericidal, Bacteriolytic and Opsonic Activity of Human Serum Against Escherichia coli," J. Med. Microbiol., 22:143-149 (1991)
Hill et al., "Comparative Opsonic Activity of Intravenous Gamma Globulin Preparations for Common Bacterial Pathogens," Am. J. Med., 76:61-66 (1984)
Gemmell et al., "Potentiation of Opsonization and Phagocytosis of Streptococcus pyogenes following Growth in the Presence of Clindamycin," J. Clin. Invest., 67:1249-1256 (1981)
Bohnsack et al., "An IgA Monoclonal Antibody Directed Against Type III Antigen on Group B Steptococci Acts as an Opsonin," J. Immunol., 143:3338-3342 (1989)
Sowter and McGee, "Evaluation of a New Technique for the Demonstration of Gonococci and Other Micro-Organisms in Host Cells," J. Clin. Pathol., 29:433-437 (1976)
S. M. Wolf, "The Treatment of Gram-Negative Bacteremia and Shock,"N. Eng. J. Med., 307:1267-1268 (1982)
G. W. Counts and M. Turck, "Screening for Cross-Reacting Capsular Polysaccharide K Antigens of Escherichia coli Using Antiserum Agar," J. Clin. Microbiol., 5:490 (1977)
L. D. Sarff et al., "Epidemiology of Escherichia Coli K1 in Healthy and Diseased Newborns," Lancet 1:1099-1104 (1975)
M. P. Weinstein et al., "The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. I. Laboratory and Epidemiologic Observations,"Rev. Infect. Dis., 5:35-53 (1983)
G. H. McCracken et al., "When to Suspect Congenital Anaerobic Infection," Hosp. Pract., 9:57 (1974)
A. S. Cross et al., "The Importance of the K1 Capsule in Invasive Infections Caused by Escherichia coli," J. Infect. Dis., 149:184-193 (1984)
D. Rowley, Br. "The Virulence of Strains of Bacterium Coli for Mice," J. Exp. Pathol., 35:528-538 (1954)
H. Smith, "Pathogenicity and the Microbe in vivo," J. Gen. Microbiol., 136:377-383 (1990)
D. E. Schiff et al., "Estimation of Protective Levels of Anti-O-Specific Lipopolysaccharide Immunoglobulin G Antibody Against Experimental Escherichia coli Infection," Infect. Immun., 61:975-980 (1993)
A. S. Cross et al., "Choice of Bacteria in Animal Models of Sepsis,"Infect. Immun., 61:2741-2747 (1993)
I. Orskov and F. Orskov, "Escherichia coli in Extra-Intestinal Infections," J. Hyg. Camp., 95:551-575 (1985)
D. E. Dietzman et al., "Neonatal Escherichia coli Septicemia--Bacterial Counts in Blood," J. Pediatr., 85:128-131 (1974)
H. S. Warren et al., "Binding and Neutralization of Endotoxin by Limulus Antilipopolysaccharide Factor," Infect. Immun., 60: 2506-2513 (1992)
R. Nagarajan et al, "Synthesis and Antibacterial Activity of N-Acyl Vancomycins," Journal of Antibiotics 41:1430-1438 (1988)
R. Nagarajan et al, "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins," Journal of Antibiotics 42:63-72 (1989)
R. Nagarajan, "Antibacterial Activities and Modes of Action of Vancomycin and Related Glycopeptides," Antimicrobial Agents and Chemotherapy 35:605-609 (1991)
M. P. Glauser et al, "Septic shock: pathogenesis," Lancet 338:732-735 (1991)
J. Cohen and M. P. Glauser, "Septic shock: treatment," Lancet 338: 736-739 (1991)
T. Muta et al, "Primary Structure of Anti-Lipopolysaccharide Factor from American Horseshoe Crab, Limulus polyphemus," Journal of Biochemistry 101:1321-1321 (1987)
J. A. Montaraz et al, "Protection against Bucella abortus in Mice with O-Polysaccharide-Specific Monoclonal Antibodies,"Infection and Immunity 51:961-963 (1986)
The Pierce Catalog, 1990, Protein Modification Sectio
December 17, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
